According to our results, others have demonstrated restored NKG2D expression levels on NK and CD8+ T cells after tumor resection in glioma patients, which was accompanied by enhanced killing activities of those effector cells against NKG2DL-positive tumor targets (63). Here, KLRK1 is linked to central nervous system cancer.